LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 8, 2019 (the “Effective Date”) by and among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and (b) PANDION THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
LEASE by and between BMR-134 COOLIDGE AVENUE LLC, a Delaware limited liability company and PANDION THERAPEUTICS, INC., a Delaware corporationLease • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 6th day of February, 2020 (the “Execution Date”), by and between BMR-134 COOLIDGE AVENUE LLC, a Delaware limited liability company (“Landlord”), and PANDION THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
ContractWarrant Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Massachusetts
THIS WARRANT AND THE UNITS ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
March 11, 2017 Jo Viney Dear Jo:Employment Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations
On behalf of Immunotolerance, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company.
PANDION THERAPEUTICS HOLDCO LLC AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of March, 2020, by and among Pandion Therapeutics Holdco LLC, a Delaware limited liability company (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
AMENDED AND RESTATED OPERATING AGREEMENT OF PANDION THERAPEUTICS HOLDCO LLC MARCH 23, 2020Operating Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED OPERATING AGREEMENT of PANDION THERAPEUTICS HOLDCO LLC, a Delaware limited liability company (the “Company”), dated as of March 20, 2020 (the “Agreement Date”), is by and among the Company and the Members (as defined below).
LICENSE AND COLLABORATION AGREEMENT by and between PANDION THERAPEUTICS, INC. and ASTELLAS PHARMA INC.License and Collaboration Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • New York
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of October 30, 2019 (the “Effective Date”), by and between Pandion Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 610 Main Street, Cambridge, MA 02139, USA (“Pandion”), and Astellas Pharma Inc., a corporation organized and existing under the laws of Japan, having its registered office at 2-5-1, Nihonbashi-Honcho Chuo-ku, Tokyo 103-8411, Japan (“Astellas”). Astellas and Pandion are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Master Services AgreementMaster Services Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • California
If, with respect to an applicable Antibody Product, any of the development milestones (iv)-(vi) listed in the table above is achieved prior to the achievement of any of the earlier listed milestones (i)-(iii) with respect to such Antibody Product and such earlier listed milestone(s) is due in accordance with the first paragraph of this Section 6, then such preceding milestones (i)-(iii), as applicable, shall be deemed achieved and the corresponding milestone payment shall be payable on achievement of the later milestone in accordance with the paragraph above.
IMMUNOTOLERANCE, INC. CONSULTING AGREEMENTConsulting Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), made this 27th day of March, 2017 is entered into by Immunotolerance, Inc., a Delaware corporation (the “Company”), and Alan Crane, an individual (the “Consultant”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Distributed Bio, Inc ANTIBODY...Antibody Library Subscription Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • California
If, with respect to an applicable Antibody Product, any of the development milestones (iv)-(vi) listed in the table above is achieved prior to the achievement of any of the earlier listed milestones (i)-(iii) with respect to such Antibody Product and such earlier listed milestone(s) is due in accordance with the first paragraph of this Section 3(d), then such preceding milestones (i)-(iii), as applicable, shall be deemed achieved and the corresponding milestone payment shall be payable on achievement of the later milestone in accordance with the paragraph above.
VIA HAND DELIVERY July 10, 2019 (as amended July 18, 2019 and sent via electronic mail) Anthony Coyle Dear Tony:Severance Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations • Massachusetts
As we discussed, your employment with Pandion Therapeutics, Inc. (the “Company”) will end effective July 17, 2019 (the “Separation Date”). As we also discussed, the period between the date of this letter agreement and the Separation Date will be a transition period, during which you will use your best efforts to, at the direction of the Company, professionally transition your duties, including cooperating with the Company’s announcement of your separation. Provided you do so, you will be eligible to receive the severance benefits described in paragraph 2 below if you sign and return this letter agreement to me by August 1, 2019 (but no earlier than the Separation Date) and do not revoke your acceptance (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of clai
July 3, 2019 Rahul Kakkar, M.D. Dear Rahul:Employment Agreement • May 22nd, 2020 • Pandion Therapeutics Holdco LLC • Pharmaceutical preparations
On behalf of Pandion Therapeutics Holdco, LLC (the “Company”), I am pleased to offer you employment. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept this offer.
